Adult ABO-incompatible liver transplantation has been known to be associated with markedly desperate outcomes. Antibody-mediated rejection (AMR) has been recognized as one of the primary causes of these desperate outcomes, but its clinical features and significance have not been well understood. Recently, some clinicians have succeeded in improving the outcome of adult ABO-incompatible liver transplantation. However, in some transplant patients undergoing these treatments, AMR has still led to graft losses. We recently encountered two patients suffering from AMR after adult ABO-incompatible liver transplantation and remedied their conditions with various therapeutic modalities including direct hepatic infusion therapy and gamma-globulin bolus infusion therapy combined with plasmapheresis. In this article, we describe the clinical features of these patients and the therapeutic strategies we applied. Furthermore, we show the histologic course of the recovery from AMR in the second patient, from whom we were able to extract serial liver biopsies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.tp.0000137264.99113.2b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Insufficient pretransplant induction therapy is associated with diffuse intrahepatic cholangiopathy in ABO-incompatible living donor liver transplantation for acute liver failure.
J Chin Med Assoc
January 2025
Division of Transplantation Surgery, Department of Surgery, Taipei Veterans General Hospital, Taiwan, ROC.
Background: ABO-incompatible liver transplantation (ABOi LT) can now be successfully performed with standard pretransplant induction therapy. For patients with chronic end-stage liver disease (ESLD), ABOi LT can achieve long-term outcomes comparable to those of blood type-compatible (ABOc) LT. Outcomes of patients with acute liver failure (ALF) who undergo urgent transplantation surgery with a limited induction period should be further investigated.
View Article and Find Full Text PDFOutcomes of massive transfusion recipients administered ABO-incompatible fresh frozen plasma.
Transfusion
January 2025
Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
Background: The provision of ABO-incompatible fresh frozen plasma (FFP) in massive transfusion (MT) has become accepted to conserve AB FFP stock. There is an evidence gap in non-trauma settings. We compare characteristics of patients who received ABO-compatible or ABO-incompatible FFP during an MT episode due to any cause of critical bleeding, and assess the impact of incompatible FFP transfusion on inhospital mortality.
View Article and Find Full Text PDFFirst ABO-Incompatible Pediatric Kidney Transplant in South Africa-A Case Report.
Pediatr Transplant
February 2025
University of Cape Town, Cape Town, South Africa.
Background: Blood group incompatibility previously represented an obstacle to living related donor (LRD) options; desensitization modalities have expanded LRD options. ABO-incompatible kidney transplants have been successful in adults and pediatric liver transplants, but to date not yet in pediatric kidney transplants in South Africa.
Case Report: Patient X is a 5 year old male with end-stage kidney failure due to Posterior Urethral Valves, requiring peritoneal dialysis pre-transplant.
Outcomes of ABO-incompatible kidney transplants with very high isoagglutinin titers: a single-center experience and literature review.
Front Immunol
December 2024
Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.
Background: ABO-incompatible kidney transplantation (ABOi-KTx) represents a possible solution to address the shortage of kidney donors. However, these transplants present immunological challenges, particularly when isoagglutinin titers are elevated pretransplant.
Methods: Single-center retrospective study describing clinical and biological outcomes of 8 patients who underwent ABOi-KTx with initial isoagglutinin titers ≥ 1/512.
ABO-identical versus incompatible platelet transfusion in patients with intracranial hemorrhage.
PLoS One
November 2024
Department of Anesthesiology, University of Virginia Health System, Charlottesville, Virginia, United States of America.
Article Synopsis
- The study investigates the effects of ABO compatibility on platelet transfusion outcomes in patients with spontaneous and traumatic intracranial hemorrhage (ICH).
- It hypothesizes that ABO-identical transfusions would result in better post-transfusion platelet increments and improved neurologic outcomes compared to incompatible transfusions.
- Results show no significant differences in platelet increments or clinical outcomes among patients receiving ABO-identical, major incompatible, or minor incompatible transfusions, suggesting ABO compatibility may not be as crucial as previously thought.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!